| Literature DB >> 28050261 |
Hui Ma1, Ji-Ping Dong1, Na Zhou1, Wei Pu1.
Abstract
In recent years, the incidence of severe infectious diseases has increased, and the number of emerging infectious diseases continues to increase. The Chinese government and military forces have paid a great deal of attention to infectious disease prevention and control, and using military-civilian cooperation, they have successfully prevented numerous severe epidemic situations, such as severe acute respiratory syndrome (SARS), influenza A (H1N1), avian influenza H5N1 and H7N9, and Ebola hemorrhagic fever, while actively maintained public health, economic development, and national construction. This paper focuses on the mechanisms of the military-cooperative emergency response to infectious diseases--the joint working mechanism, the information-sharing mechanism, the research collaboration mechanism, and the joint disposal mechanism--and presents a sorted summary of the practices and experiences of cooperative emergency responses to infectious diseases. In the future, the Chinese military and the civilian sector will further strengthen the cooperative joint command system and emergency rescue force and will reinforce their collaborative information-sharing platform and technical equipment system to further improve military-civilian collaborative emergency infectious diseases disposal, advance the level of infectious disease prevention and control, and maintain public health.Entities:
Keywords: Emergency response; Infectious disease; Military-civilian cooperation
Year: 2016 PMID: 28050261 PMCID: PMC5203723 DOI: 10.1186/s40779-016-0109-y
Source DB: PubMed Journal: Mil Med Res ISSN: 2054-9369
Infectious disease emergency events and the military-civilian cooperative response
| Infectious disease events | Year | Military-civilian contributions |
|---|---|---|
| SARS | 2003 | First isolation of the virus; sequencing of the entire virus genome; development of rapid diagnosis assays; establishment of SARS-designated hospitals and treatment of the patients |
| H5N1 avian flu | 2004 to 2005 | Large-scale industrial development of the Tamiflu equivalent, Oseltamivir (brand name KeWei) |
| H1N1 flu | 2009 | Confirmation of first input H1N1 infected case; development of rapid diagnosis assays and RT-PCR; development of Peramivir Trihydrate and H1N1 flu vaccine |
| H7N9 flu | 2013 to 2016 | Development of rapid diagnosis assays and RT-PCR; development of Peramivir and sodium chloride injection |
| Ebola hemorrhagic fever | 2014 to 2015 | Deployment of testing teams and mobile hospitals; treatment of patients and training of the health care workers; establishment and operation of biosafety III laboratory; development of Ebola drug MIL 77 and vaccine |
| Zika virus infection | 2015 to 2016 | Confirmation of first input Zika virus infection case; isolation of Zika virus strains; gene sequencing of the first imported Zika virus; development of rapid diagnosis assays |